Clinical Trial Update: JSKN003 Combined Treatment of HER2-positive Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of JSKN003 combined therapy for HER2-positive gastric cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• JSKN003

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: NOT_YET_RECRUITING